


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO STRATEGIC COOPERATION WITH XTALPI

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “**Company**” or “**Hanx Biopharmaceuticals**”) on a voluntary basis.

Hanx Biopharmaceuticals is pleased to announce that the Company and Shenzhen XtalPi Technology Co., Ltd. (“**XtalPi**”), an independent third party of the Company, have recently formally entered into the Strategic Cooperation Framework Agreement and the XtalPi Science Technology Platform Use License Agreement (collectively, the “**Agreements**”), to explore the application of AI for Science in fields such as antibody design, innovative molecule design and drug R&D process optimization.

Pursuant to the Agreements, the Company intends to procure and use, according to its actual R&D needs, the relevant services and usage quotas of the XtalPi Science platform provided by XtalPi, and XtalPi will provide the Company with the corresponding platform capabilities and necessary technical support.

This cooperation centers on the commercial procurement and application of XtalPi Science products and services, and aims to support the Company in flexibly using advanced AI models and computing capabilities in R&D scenarios relating to biologics, XDC and other innovative drugs. The parties intend to establish a long-term and stable cooperative relationship on the basis of this application of the products and services.

In respect of the relevant platform capabilities and services that the Company intends to procure and use, the preliminary application scenarios it intends to explore include, but are not limited to:

1. Leveraging AI models, related computing capabilities and intelligent agents to assist in the design, analysis and optimization of biologic drug candidate molecules;
2. Leveraging AI models, related computing capabilities and intelligent agents to design XDC payloads with special functions;
3. Leveraging AI models, related computing capabilities and intelligent agents to customise the design of other candidate molecules and key functional modules.

The aforementioned applications are, at the current stage, being advanced by the Company in accordance with its own R&D plans and needs. The specific scale of procurement, scope of services, implementation arrangements and other commercial terms will be separately determined by the parties through specific orders or subsequent agreements based on actual needs. The parties may also, based on business needs, further discuss expanding the scale of use and scope of application of XtalPi Science services.

This cooperation will optimize the Company's biologics screening and molecule optimization processes, and is expected to enhance R&D efficiency and success rates, shorten R&D cycles, reduce R&D costs, and accelerate the Company's progress in First-in-Class (FIC) and Best-in-Class (BIC) drug R&D. The relevant outcomes will further enrich the Company's R&D pipeline, strengthen its technological advantages and core competitiveness, and provide strong support for the Company's long-term development and sustainable operations.

ABOUT HANX BIOPHARMACEUTICALS

Established in 2014, HanX Biopharmaceuticals (Wuhan) Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development. The Company strives to develop next-generation immunotherapies to provide global patients with affordable, safe, and effective medical solutions, addressing the challenges of major diseases. Upholding its innovation-driven mission and vision, Hanx Biopharmaceuticals focuses on discovering, developing, and commercializing products for the precision treatment of cancer and autoimmune diseases. The Company is committed to meeting unmet medical needs worldwide, advancing disease prevention, control, and ultimately elimination, and contributing to global health initiatives.

ABOUT XTALPI

Shenzhen XtalPi Technology Co., Ltd. (a wholly-owned subsidiary of XtalPi Holdings Limited, a company whose shares are listed on the Stock Exchange of Hong Kong Limited (stock code: 2228)) was founded in 2015 by three MIT physicists. It is an AI-powered and robotics-driven innovative R&D platform based on quantum physics. By integrating quantum physics-based first-principles calculation, AI, high-performance cloud computing, and scalable and standardized robotic automation, XtalPi provides drug and material science R&D solutions and services to global and domestic companies in industries such as pharmaceuticals and material sciences (including agricultural technology, energy, new chemicals, and cosmetics). To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, as at the date of this announcement, each of XtalPi and XtalPi Holdings Limited is an independent third party of the Company and its connected persons.

Warning Statement under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The relevant products may not ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, September 21, 2026

As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.